246C10
目录号 : GC63985246C10是一种可电离的阳离子脂质(pKa=6.75)。
Cas No.:2635329-26-7
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
246C10 is an ionizable cationic lipid (pKa = 6.75)[1]. 246C10 can be combined with lipids such as dioleylphosphatidylethanolamine (DOPE), cholesterol, and C16-PEG2000 ceramide (PEG-lipid) to generate lipid nanoparticles (LNPs) for targeted delivery of RNA therapeutics into cells[2, 3]. 246C10 was formulated into LNPs together with mRNA encoding luciferase (mFLuc) and DOPE, cholesterol, PEG-lipid, and mannose-PEG lipid. When injected intravenously into ApoE knockout mice, it significantly increased luciferase expression in the liver[4]. Targeted gene editing of AT in mouse livers using 246C10 LNPs loaded with Cas9 and sgRNA inhibited the production of mouse antithrombin (AT) without introducing off-target effects, liver toxicity, and a large anti-Cas9 immune response[5].
References:
[1] Tang X, Zhang Y, Han X. Ionizable Lipid Nanoparticles for mRNA Delivery[J]. Advanced NanoBiomed Research, 2023, 3(8): 2300006.
[2] Jin H, Jeong M, Lee G, et al. Engineered lipid nanoparticles for the treatment of pulmonary fibrosis by regulating epithelial‐mesenchymal transition in the lungs[J]. Advanced Functional Materials, 2023, 33(7): 2209432.
[3] Wu S, Lin L, Shi L, et al. An overview of lipid constituents in lipid nanoparticle mRNA delivery systems[J]. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2024, 16(4): e1978.
[4] Kim M, Jeong M, Hur S, et al. Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver[J]. Science advances, 2021, 7(9): eabf4398.
[5] Liu Z, Li Z, Li B. Nonviral delivery of CRISPR/Cas systems in mRNA format[J]. Advanced NanoBiomed Research, 2022, 2(11): 2200082.
246C10是一种可电离的阳离子脂质(pKa=6.75)[1]。246C10可以与二油基磷脂酰乙醇胺 (DOPE)、胆固醇、C16-PEG2000神经酰胺(PEG-lipid)等脂质结合,用于生成脂质纳米颗粒(LNP),用于将RNA治疗药物靶向递送到细胞中[2, 3]。246C10与编码荧光素酶(mFLuc)的mRNA以及DOPE、胆固醇、PEG-脂质和甘露糖-PEG脂质一起配制成LNP,通过静脉注射处理ApoE敲除小鼠,可显著增加肝脏中的荧光素酶表达[4]。使用负载Cas9和sgRNA的246C10 LNP对小鼠肝脏中的AT进行靶向基因编辑,可抑制小鼠抗凝血酶(AT)的生成,而不会引入脱靶效应、肝毒性和大量抗Cas9免疫反应[5]。
Cas No. | 2635329-26-7 | SDF | Download SDF |
分子式 | C58H120N4O4 | 分子量 | 937.6 |
溶解度 | 储存条件 | Store at -20°C | |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.0666 mL | 5.3328 mL | 10.6655 mL |
5 mM | 0.2133 mL | 1.0666 mL | 2.1331 mL |
10 mM | 0.1067 mL | 0.5333 mL | 1.0666 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。